Minimally Invasive Atlantoaxial Lateral Mass Joint Fusion (MIS-PALF) As a Surgical Treatment of Atlantoaxial Dislocation

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-80
SponsorPeking University Third Hospital

About this trial

The conventional treatment for atlantoaxial dislocation is atlantoaxial fixation and fusion using the Goel-Harms technique, which involves a midline incision, dissection of the occipital muscle group, and is associated with disadvantages such as damage to the posterior ligament and muscle, high incidence of postoperative occipital cervical pain, and significant blood loss due to intraoperative bleeding and postoperative drainage. Since 2013, various studies have reported minimally invasive posterior atlantoaxial lateral mass joint fusion techniques through muscle spaces, but previous studies were all case reports, without sufficient reliability and controlled studies. The Department of Orthopedics at Peking University Third Hospital has been using the minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion (Mis-PALF) technique for the treatment of atlantoaxial dislocation since 2015, with preliminary good clinical results. In order to further compare the advantages and disadvantages of the two surgical methods from a larger sample, a randomized controlled study is planned. The patients will be randomly divided into two groups, with the experimental group receiving the Mis-PALF surgery and the control group receiving open atlantoaxial fusion and fixation. There will be a 1-2 year follow-up to compare the safety and effectiveness of the two surgical methods for the treatment of atlantoaxial dislocation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age range from 0 to 80 years old, regardless of gender

Diagnosed with atlantoaxial dislocation, suitable for posterior surgical treatment

Index of assessment integrity

Agree to participate in the study and sign the informed consent

Disqualifiers

Atlantoaxial dislocation without surgical treatment

Atlantoaxial dislocation treated by other operation, such as TARP

Trial design

Design model

Parallel

Treatments tested in this trial

  • minimal invasive surgery-posterior atlantoaxial lateral mass joint fusion

    Procedure/Surgery

    Make a 4.5 cm incision along the median line and then dissect the trapezius, splenius capitis, and semispinalis capitis muscle laterally 1.5 cm off the median line. Retract the obliquus capitis inferior muscle to expose the C1-C2 intra-articular space. Remove the articular cartilage, insert allogenic granular bone and 3D-printed cage. Place the screws and rod in the same positions as conventional surgery, and the operation is completed.

  • Open atlantoaxial fixation and fusion

    Procedure/Surgery

    The Goel-Harms procedure will be used in the control group. Screws and rods are placed in the same position as in the experimental group, and a negative-pressure drain was placed until daily drainage was \<50 mL.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: Minimal invasive surgery armExperimental treatment 1 intervention
Group B: Open atlantoaxial fixation and fusion armActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Perioperative Blood Loss

Blood loss due to intraoperative bleeding and postoperative drainage.

Time frame
2 weeks
2

Postoperative Stay

The time from the completion of surgery to the patient leaving hospital.

Time frame
2 weeks
3

Level of Occipitocervical Pain

The level of patients' occipitocervical pain is described by Numerical Rating Scale, from zero to ten, and ten means the most pain.

Time frame
12 months
4

Main location of occipitocervical pain

The location of patients' occipitocervical pain is indicated by patients on a diagram illustrating the anatomical regions of the head and neck.

Time frame
12 months

Secondary outcomes

1

Incidence of Adverse Events

This metric is defined as the proportion of adverse events that manifest during the study's duration relative to the total number of patients enrolled. Adverse events encompass a range of critical factors, including but not limited to: Neurological deterioration, Incision infection, Vascular injury, Airway obstruction, Poor reduction, Unplanned readmission and re-surgery, Internal fixation failure, Fusion failure, Surgical-related lower cervical spine deformities.

Time frame
12 months
2

Atlantoaxial Reduction Rate

To gauge the effectiveness of the surgical interventions in achieving atlantoaxial reduction, postoperative CT scans of the head and neck will be conducted. Measurements will be taken of the distance between the odontoid process and key reference lines, including Chamberlain's line (CL), Wackenheim line (WL), McRae line (ML), and atlantodental interval (ADI). The reduction rate will be calculated by comparing the postoperative measurements to the preoperative values, expressed as a ratio.

Time frame
12 months
3

Bone Graft Fusion Rate

Evaluation of the proportion of patients exhibiting successful bone fusion between the atlas and axis will be conducted through postoperative three-dimensional CT examinations of the cervical spine. The bone graft fusion rate will be determined by calculating the number of patients with evident fusion relative to the total number of patients enrolled.

Time frame
12 months
4

Improvement Rate of Quality of Life

The quality of life for each patient will be assessed using the Short Form 12-Item(SF-12) Health Survey. SF-12 scores ranges from 0 to 100, and 100 usually means healthier in a certain dimension. The improvement rate in quality of life will be calculated based on the preoperative and postoperative differences in SF-12 scores. This indicator offers insights into the impact of surgical interventions on patients' overall well-being and quality of life, providing a vital perspective on treatment effectiveness.

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University Third Hospital

Lead sponsor

Hebei Medical University Third Hospital

Collaborator

Shanxi Bethune Hospital

Collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborator

Second Affiliated Hospital of Wenzhou Medical University

Collaborator

Tianjin People's Hospital

Collaborator

First Affiliated Hospital of Kunming Medical University

Collaborator

Daping Hospital of Army Medical University

Collaborator

Shengjing Hospital

Collaborator

Third Bethune Hospital of Jilin University

Collaborator

This trial is not recruiting at the moment. You can still explore other options: